AN2 Therapeutics Inc (ANTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AN2 Therapeutics Inc (ANTX) has a cash flow conversion efficiency ratio of -0.099x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.24 Million) by net assets ($53.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AN2 Therapeutics Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
AN2 Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how AN2 Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
AN2 Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AN2 Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Associated British Foods PLC
LSE:ABF
|
0.067x |
|
Media Capital
LS:MCP
|
-0.013x |
|
Mpact Limited
JSE:MPT
|
-0.008x |
|
Titan Minerals Ltd
AU:TTM
|
-0.013x |
|
Alkim Kagit Sanayi ve Ticaret AS
IS:ALKA
|
1.752x |
|
WCT Holdings Bhd
KLSE:9679
|
0.004x |
|
Froch Enterprise Co Ltd
TW:2030
|
-0.032x |
|
Circus SE
XETRA:CA1
|
N/A |
Annual Cash Flow Conversion Efficiency for AN2 Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of AN2 Therapeutics Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see ANTX company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $53.06 Million | $-29.83 Million | -0.562x | +6.57% |
| 2024-12-31 | $81.85 Million | $-49.26 Million | -0.602x | -40.83% |
| 2023-12-31 | $124.70 Million | $-53.29 Million | -0.427x | -21.79% |
| 2022-12-31 | $95.37 Million | $-33.46 Million | -0.351x | -6.04% |
| 2021-12-31 | $61.91 Million | $-20.48 Million | -0.331x | +83.03% |
| 2020-12-31 | $2.75 Million | $-5.36 Million | -1.950x | -277.50% |
| 2019-12-31 | $4.81 Million | $-2.49 Million | -0.517x | -- |
About AN2 Therapeutics Inc
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15… Read more